Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 548

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 548
---
 2 (5) |
| II                         |     |   0 (0) |     |  1 (20) |     |  1 (25) |     |    0 (0) |     |    0 (0) |     |     0 (0) |     |      1 (33) |     |       1 (17) |     |        0 (0) |     |  4 (11) |
| III                        |     |   0 (0) |     |   0 (0) |     |   0 (0) |     |    0 (0) |     |   2 (33) |     |     0 (0) |     |      1 (33) |     |        0 (0) |     |        0 (0) |     |   3 (8) |
| IV                         |     |  1 (50) |     |  3 (60) |     |  2 (50) |     |   2 (50) |     |   2 (33) |     |   3 (100) |     |      1 (33) |     |       4 (83) |     |        0 (0) |     | 18 (49) |
| Missing                    |     |  1 (50) |     |   0 (0) |     |  1 (25) |     |   2 (50) |     |   1 (17) |     |     0 (0) |     |       0 (0) |     |       1 (40) |     |      4 (100) |     | 10 (27) |

360

Safety Evaluating the safety and tolerability of KVA12123 is one of the primary objectives of VISTA-101.As of January 31, 2025, enrollment was completed in all six monotherapy cohorts with 24 patients dosed in six different dosing levels. KVA12123 was well tolerated at all doses and no dose limiting toxicities (“DLT”) were observed. All KVA12123 treatment emergent adverse events were grades 1-2. Figure 16: VISTA-101KVA12123 was well tolerated at all dose levels in the six monotherapy cohorts and the first two combination cohorts (30 and